Cargando…

Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications

SETTING: Rifampicin (RMP) drives treatment response in drug-susceptible tuberculosis. Low RMP concentrations increase the risk of poor outcomes, and drug quality needs to be excluded as a contributor to low RMP exposure. OBJECTIVES AND DESIGN: We performed an open-label, three-way cross-over study o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Court, R., Chirehwa, M. T., Wiesner, L., Wright, B., Smythe, W., Kramer, N., McIlleron, H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Union Against Tuberculosis and Lung Disease 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905389/ https://www.ncbi.nlm.nih.gov/pubmed/29663959 http://dx.doi.org/10.5588/ijtld.17.0697

Ejemplares similares

Current research toward optimizing dosing of first-line antituberculosis treatment
por: McIlleron, Helen, et al.
Publicado: (2018)

Bedaquiline exposure in pregnancy and breastfeeding in women with rifampicin‐resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2022)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis
por: Court, R. G., et al.
Publicado: (2018)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
por: Court, Richard, et al.
Publicado: (2021)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
por: Svensson, Elin M., et al.
Publicado: (2017)

Relative Bioavailability of Rifampicin in Four Chinese Fixed-dose Combinations Compared with Rifampicin in Free Combinations
por: Zhu, Hui, et al.
Publicado: (2015)

The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy
por: Decloedt, Eric H., et al.
Publicado: (2012)

Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling
por: Heidebrecht, Christine L., et al.
Publicado: (2016)

Isoniazid, Pyrazinamide and Rifampicin Content Variation in Split Fixed-Dose Combination Tablets
por: Pouplin, Thomas, et al.
Publicado: (2014)

Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus‐associated tuberculosis
por: Schutz, Charlotte, et al.
Publicado: (2020)

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
por: Naiker, Suhashni, et al.
Publicado: (2014)

Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
por: Abdelgawad, Noha, et al.
Publicado: (2022)

Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
por: Chabala, Chishala, et al.
Publicado: (2023)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial
por: Wasserman, Sean, et al.
Publicado: (2021)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

A Decision Tree for Rapid Quality Assurance and Control of Rifampicin-Containing Oral Dosage Forms for Global Distribution for Tuberculosis Treatment
por: Ashokraj, Y., et al.
Publicado: (2008)

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)

Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2012)

Retrospective record review of pregnant women treated for rifampicin-resistant tuberculosis in South Africa
por: van der Walt, Martie, et al.
Publicado: (2020)

Isoniazid and Rifampicin Resistance-Conferring Mutations in Mycobacterium tuberculosis Isolates from South Africa
por: Traoré, Afsatou Ndama, et al.
Publicado: (2023)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

Correction: Coadministration of Lopinavir/Ritonavir and Rifampicin in HIV and Tuberculosis Co-Infected Adults in South Africa
por: Murphy, Richard A., et al.
Publicado: (2013)

Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis
por: Bouton, Tara C., et al.
Publicado: (2019)

Development and Characterization of Pharmaceutical Systems Containing Rifampicin
por: Dan Córdoba, Antonella V., et al.
Publicado: (2023)

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
por: Sinxadi, Phumla Z, et al.
Publicado: (2012)

Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study
por: Berhanu, Rebecca, et al.
Publicado: (2016)

Maternal and Infant Outcomes Among Pregnant Women Treated for Multidrug/Rifampicin-Resistant Tuberculosis in South Africa
por: Loveday, Marian, et al.
Publicado: (2020)

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study
por: Ndjeka, Norbert, et al.
Publicado: (2022)

A Micro-Configured Multiparticulate Reconstitutable Suspension Powder of Fixed Dose Rifampicin and Pyrazinamide: Optimal Fabrication and In Vitro Quality Evaluation
por: Rampedi, Penelope N., et al.
Publicado: (2022)

An overview of the quality assurance programme for HIV rapid testing in South Africa: Outcome of a 2-year phased implementation of quality assurance program
por: Woldesenbet, Selamawit Alemu, et al.
Publicado: (2019)

Oral pyridoxine can substitute for intravenous pyridoxine in managing patients with severe poisoning with isoniazid and rifampicin fixed dose combination tablets: a case report
por: Dilrukshi, M. D. S. A., et al.
Publicado: (2017)

Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART
por: Rawizza, Holly E, et al.
Publicado: (2020)

Pharmacometrics: Opportunity for Reducing Disease Burden in the Developing World: The Case of Africa
por: Pillai, G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0ij4fejlpkejg2h5avev0r50ei